ImmunityBio’s ANKTIVA Approved in 33 Countries Amid Rapid Global Expansion

ImmunityBio (IBRX) has significantly expanded its global footprint, with its flagship drug ANKTIVA now approved in 33 countries. A substantial number of these regulatory approvals were secured just this week, marking a period of intense international momentum for the biotech firm. This follows recent key authorizations from the European Commission and authorities in the Kingdom of Saudi Arabia. Beyond new approvals, the treatment is demonstrating robust commercial growth in markets where it is already established. The company’s rapid scaling is evident as it has entered four major regulatory jurisdictions in less than two years since its initial FDA approval. Investors remain optimistic about the company’s ability to convert these widespread approvals into diversified global revenue streams.